Willy Hugo

17.1k total citations · 4 hit papers
44 papers, 4.3k citations indexed

About

Willy Hugo is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Willy Hugo has authored 44 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Molecular Biology, 21 papers in Oncology and 14 papers in Immunology. Recurrent topics in Willy Hugo's work include Cancer Immunotherapy and Biomarkers (14 papers), Melanoma and MAPK Pathways (13 papers) and Immunotherapy and Immune Responses (7 papers). Willy Hugo is often cited by papers focused on Cancer Immunotherapy and Biomarkers (14 papers), Melanoma and MAPK Pathways (13 papers) and Immunotherapy and Immune Responses (7 papers). Willy Hugo collaborates with scholars based in United States, Singapore and Australia. Willy Hugo's co-authors include Roger S. Lo, Antoni Ribas, Lu Sun, Xiangju Kong, Gatien Moriceau, Aayoung Hong, Thomas G. Graeber, Hubing Shi, Douglas B. Johnson and Jeffrey A. Sosman and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

In The Last Decade

Willy Hugo

40 papers receiving 4.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

2017 1.3k citations Ángel García-Díaz, Daniel Sanghoon Shin et al. Cell Reports profile →
Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy

2013 715 citations Hubing Shi, Willy Hugo et al. Cancer Discovery profile →
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma

2014 427 citations Judith M. Müller, Oscar Krijgsman et al. Nature Communications profile →
Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance

2015 412 citations Willy Hugo, Hubing Shi et al. Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Willy Hugo United States	20	2.5k	2.4k	1.4k	644	442	44	4.3k
Thinle Chodon United States	22	3.3k 1.3×	3.2k 1.3×	1.4k 1.0×	461 0.7×	422 1.0×	33	5.2k
Clemens Krepler United States	23	2.6k 1.0×	2.3k 1.0×	1.1k 0.8×	755 1.2×	331 0.7×	75	4.2k
Laura Soucek Spain	32	3.7k 1.4×	1.7k 0.7×	855 0.6×	858 1.3×	305 0.7×	54	5.0k
Kimberly B. Dahlman United States	21	2.3k 0.9×	1.7k 0.7×	451 0.3×	575 0.9×	460 1.0×	38	3.2k
James S. Wilmott Australia	36	2.8k 1.1×	4.4k 1.8×	2.4k 1.7×	798 1.2×	1.0k 2.3×	139	6.4k
Nathalie Dhomen United Kingdom	19	2.2k 0.9×	1.6k 0.7×	474 0.3×	585 0.9×	279 0.6×	34	3.2k
Kristel Kemper Netherlands	23	2.7k 1.1×	2.9k 1.2×	630 0.4×	1.1k 1.7×	329 0.7×	35	4.7k
María Romina Girotti Argentina	21	1.6k 0.6×	1.4k 0.6×	827 0.6×	628 1.0×	302 0.7×	44	3.0k
Ester Simeone Italy	33	1.5k 0.6×	3.2k 1.3×	1.6k 1.1×	366 0.6×	689 1.6×	114	4.4k
Hetal Patel United Kingdom	19	2.3k 0.9×	2.1k 0.9×	476 0.3×	469 0.7×	334 0.8×	35	3.5k

Countries citing papers authored by Willy Hugo

Since Specialization

Citations

This map shows the geographic impact of Willy Hugo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Willy Hugo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Willy Hugo more than expected).

Fields of papers citing papers by Willy Hugo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Willy Hugo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Willy Hugo. The network helps show where Willy Hugo may publish in the future.

Co-authorship network of co-authors of Willy Hugo

This figure shows the co-authorship network connecting the top 25 collaborators of Willy Hugo. A scholar is included among the top collaborators of Willy Hugo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Willy Hugo. Willy Hugo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lechner, Melissa G., Willy Hugo, Alexandra Drakaki, et al.. (2023). Clonally expanded, thyrotoxic effector CD8 ⁺ T cells driven by IL-21 contribute to checkpoint inhibitor thyroiditis. Science Translational Medicine. 15(696). eadg0675–eadg0675. 19 indexed citations

Sun, Lu, Yanjun Zhang, Robert M. Prins, et al.. (2023). Antigen presentation by clonally diverse CXCR5+ B cells to CD4 and CD8 T cells is associated with durable response to immune checkpoint inhibitors. Frontiers in Immunology. 14. 1176994–1176994. 18 indexed citations

Sun, Lu, Jenny C. Kienzler, Alex Lee, et al.. (2023). Immune checkpoint blockade induces distinct alterations in the microenvironments of primary and metastatic brain tumors. Journal of Clinical Investigation. 133(17). 18 indexed citations

Wang, Yan, Mandy I. Cheng, Willy Hugo, et al.. (2022). Pathogenic TNF-α drives peripheral nerve inflammation in an Aire-deficient model of autoimmunity. Proceedings of the National Academy of Sciences. 119(4). 22 indexed citations

Hugo, Willy, et al.. (2022). The roles of TGF-β and VEGF pathways in the suppression of antitumor immunity in melanoma and other solid tumors. Pharmacology & Therapeutics. 240. 108211–108211. 42 indexed citations

Lechner, Melissa G., Mandy I. Cheng, Marissa S. Pioso, et al.. (2022). Inhibition of IL-17A Protects against Thyroid Immune-Related Adverse Events while Preserving Checkpoint Inhibitor Antitumor Efficacy. The Journal of Immunology. 209(4). 696–709. 29 indexed citations

Lee, Alex, Lu Sun, Aaron Mochizuki, et al.. (2021). Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma. Nature Communications. 12(1). 6938–6938. 135 indexed citations

Zhang, Dongyun, Willy Hugo, Hui Miao, et al.. (2021). A human ACTH-secreting corticotroph tumoroid model. EBioMedicine. 66. 103294–103294. 10 indexed citations

Wang, Xuefeng, Xiaoqing Yu, Michael Krauthammer, et al.. (2020). The Association of MUC16 Mutation with Tumor Mutation Burden and Its Prognostic Implications in Cutaneous Melanoma. Cancer Epidemiology Biomarkers & Prevention. 29(9). 1792–1799. 15 indexed citations

10.

Song, Chunying, Marco Piva, Lu Sun, et al.. (2017). Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation. Cancer Discovery. 7(11). 1248–1265. 109 indexed citations

11.

Hong, Aayoung, Gatien Moriceau, Lu Sun, et al.. (2017). Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma. Cancer Discovery. 8(1). 74–93. 72 indexed citations

12.

García-Díaz, Ángel, Daniel Sanghoon Shin, Blanca Homet Moreno, et al.. (2017). Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression. Cell Reports. 19(6). 1189–1201. 1327 indexed citations breakdown →

13.

Pan, Min, Michael A. Reid, Xazmin H. Lowman, et al.. (2016). Regional glutamine deficiency in tumours promotes dedifferentiation through inhibition of histone demethylation. Nature Cell Biology. 18(10). 1090–1101. 276 indexed citations

14.

Moriceau, Gatien, Willy Hugo, Aayoung Hong, et al.. (2015). Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF/MEK Cotargeting but Result in Melanoma Drug Addiction. Cancer Cell. 27(2). 240–256. 237 indexed citations

15.

Hugo, Willy, Hubing Shi, Lu Sun, et al.. (2015). Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance. Cell. 162(6). 1271–1285. 412 indexed citations breakdown →

16.

Müller, Judith M., Oscar Krijgsman, Jennifer Tsoi, et al.. (2014). Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. Nature Communications. 5(1). 5712–5712. 427 indexed citations breakdown →

17.

Marusiak, Anna A., Willy Hugo, Eleanor W. Trotter, et al.. (2014). Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors. Nature Communications. 5(1). 3901–3901. 63 indexed citations

18.

Shi, Hubing, Willy Hugo, Xiangju Kong, et al.. (2013). Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy. Cancer Discovery. 4(1). 80–93. 715 indexed citations breakdown →

19.

Shi, Hubing, Aayoung Hong, Xiangju Kong, et al.. (2013). A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition. Cancer Discovery. 4(1). 69–79. 133 indexed citations

20.

Chua, Hon Nian, et al.. (2009). A Probabilistic Graph‐Theoretic Approach to Integrate Multiple Predictions for the Protein–Protein Subnetwork Prediction Challenge. Annals of the New York Academy of Sciences. 1158(1). 224–233. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact